as of 08-27-2026 4:00pm EST
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SCOTTSDALE |
| Market Cap: | 4.8B | IPO Year: | 2021 |
| Target Price: | $9.83 | AVG Volume (30 days): | 4.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $4.78 - $12.96 | Next Earning Date: | 05-07-2026 |
| Revenue: | $1,424,285,000 | Revenue Growth: | 13.85% |
| Revenue Growth (this year): | 17.18% | Revenue Growth (next year): | 14.02% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | 110.0M | FCF Growth: | +28.39% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Director
Avg Cost/Share
$12.68
Shares
7,500
Total Value
$95,100.00
Owned After
97,093
SEC Form 4
Director
Avg Cost/Share
$11.51
Shares
500,000
Total Value
$5,755,000.00
Owned After
2,970,810
SEC Form 4
10% Owner
Avg Cost/Share
$10.62
Shares
13,643,207
Total Value
$144,890,858.34
Owned After
98,101,407
SEC Form 4
Chief Technology Officer
Avg Cost/Share
$10.85
Shares
44,394
Total Value
$481,674.90
Owned After
247,446
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$10.85
Shares
47,912
Total Value
$519,845.20
Owned After
281,289
SEC Form 4
Director
Avg Cost/Share
$10.13
Shares
894,337
Total Value
$9,059,633.81
Owned After
656,560
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| DeLuca Teresa | LFST | Director | Aug 14, 2026 | Sell | $12.68 | 7,500 | $95,100.00 | 97,093 | |
| Burdick Kenneth A | LFST | Director | Aug 11, 2026 | Sell | $11.51 | 500,000 | $5,755,000.00 | 2,970,810 | |
| TPG GP A, LLC | LFST | 10% Owner | Aug 10, 2026 | Sell | $10.62 | 13,643,207 | $144,890,858.34 | 98,101,407 | |
| Paunovich Vukasin | LFST | Chief Technology Officer | Aug 10, 2026 | Sell | $10.85 | 44,394 | $481,674.90 | 247,446 | |
| Miller Lisa K | LFST | Chief Operating Officer | Aug 10, 2026 | Sell | $10.85 | 47,912 | $519,845.20 | 281,289 | |
| Bessler Robert | LFST | Director | Jun 26, 2026 | Sell | $10.13 | 894,337 | $9,059,633.81 | 656,560 |
SEC 8-K filings with transcript text
Aug 6, 2026 · 85% conf.
1D
-7.41%
$9.87
Act: +1.69%
5D
-6.90%
$9.92
20D
-9.43%
$9.66
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1786198193.fe95cf2e
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
May 7, 2026 · 100% conf.
1D
-7.29%
$8.20
Act: -12.25%
5D
-6.89%
$8.24
Act: -10.85%
20D
-9.17%
$8.04
Act: -16.27%
2 lfst-ex99_1.htm
Exhibit 99.1
Investor Relations Contact
Monica Prokocki
VP of Finance & Investor Relations
602-767-2100
investor.relations@lifestance.com
LifeStance Reports First Quarter 2026 Results
SCOTTSDALE, Ariz. – May 7, 2026 – LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the first quarter ended March 31, 2026.
(All results compared to prior-year comparative period, unless otherwise noted)
2026 Highlights and FY 2026 Outlook
• Revenue of $403.5 million increased 21% compared to revenue of $333.0 million
• Clinician base increased 11% to 8,349 clinicians, a sequential net increase of 309 in the first quarter
• First quarter visit volumes increased 18% to 2.5 million
• Net income of $14.2 million compared to net income of $0.7 million
• Adjusted EBITDA of $51.1 million compared to Adjusted EBITDA of $34.6 million
• Net cash provided by operations of $33.1 million in the first quarter
• Free Cash Flow generation of $22.3 million in the first quarter
• For full year 2026, raising revenue expectations to $1.640 billion to $1.680 billion, Center Margin expectations to $547 million to $571 million, and Adjusted EBITDA of $200 million to $220 million
“We delivered an exceptional quarter to begin the year, highlighted by strong revenue growth of 21%, net income growth of $13.5 million, and Adjusted EBITDA growth of 48%,” said Dave Bourdon, CEO of LifeStance. “Our performance demonstrates that our differentiated model is meeting the societal trend of growing demand for mental healthcare. We also took an important step forward in our commitment to clinical excellence by announcing an outcomes study on approximately 180,000 LifeStance patients that showed roughly three quarters reported clinically significant improvement in anxiety and depression.”
Financial Highlights
Y/Y
(in millions)
Total revenue
$
403.5
$
333.0
21
%
Income from operations
22.3
1.6
NM
Center Margin
135.9
109.8
24
%
Net income
14.2
0.7
NM
Adjusted EBITDA
51.1
34.6
48
%
As % of Total revenue:
Income from operations
5.5
%
0.5
%
Center Margin
33.7
%
33.0
%
Net income
3.5
%
0.2
%
Adjusted EBITDA
12.7
%
10.4
%
NM - not meaningful
(All results compared to prior-year period, unless otherwise noted)
• Revenue grew 21% to $403.5 million. Revenue growth in the first quarter was driven primarily by higher visit volumes from net clinician growth, improved clinician productivity, and higher total revenue per visit.
• income from operations was $22.3 million and net income was $14.2 million.
• Center Margin grew 24% to $135.9 million, or 33.7% of total revenue.
• Adjusted EBITDA increased 48% to $51.1 million, or 12.7% of total revenue. Adjusted EBITDA as a percentage of revenue increased in the first quarter as a result of higher total revenue per visit, lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses.
Balance Sheet, Cash Flow, and Capital Allocation
For the three months ended March 31, 2026, LifeStance generated $33.1 million cash flow from operations. The Company ended the first quarter with cash of $194.8 million and net long-term debt of $262.5 million.
2026 Guidance
LifeStance is providing the following outlook for 2026:
• The Company is raising full year revenue to $1.640 billion to $1.680 billion, Center Margin to $547 million to $571 million, and Adjusted EBITDA to $200 million to $220 million.
• For the second quarter of 2026, the Company expects total revenue of $405 million to $425 million, Center Margin of $135 million to $147 million, and Adjusted EBITDA of $50 million to $60 million.
Conference Call, Webcast Information, and Presentations
LifeStance will hold a conference call today, May 7, 2026 at 8:30 a.m. Eastern Time to discuss the first quarter 2026 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 8795477 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.
About LifeStance Health Group, Inc.
Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance and its supported
Feb 25, 2026 · 100% conf.
1D
+3.75%
$7.69
Act: -6.07%
5D
+10.71%
$8.20
Act: -1.08%
20D
+12.62%
$8.35
8-K
0001845257false00018452572026-02-252026-02-25
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 25, 2026
LifeStance Health Group, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40478
86-1832801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
4800 N. Scottsdale Road Suite 2500
Scottsdale, Arizona
85251
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 602 767-2100
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 25, 2026, LifeStance Health Group, Inc. ("LifeStance Health Group", "LifeStance" or the "Company") issued a press release announcing its results of operations for the fourth quarter and full year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1. The information furnished under Item 2.02 of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors' Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 25, 2026, Kenneth Burdick, Executive Chairman of the Board of Directors of the Company (the “Board”) announced his planned transition to non-executive Chairman of the Board effective March 16, 2026. Mr. Burdick’s transition is not due to and does not involve any disagreement with management or the Board related to the Company’s operations, policies or practices. Following the transition, Mr. Burdick will participate in the Company’s standard non-employee director compensation program and will be entitled to receive an annual cash retainer of $200,000 as non-executive chairperson of the Board of Directors of the Company and an annual grant of restricted stock units (“RSUs”) with a grant date fair market value of approximately $500,000 in that capacity. Item 7.01 Regulation FD Disclosure. A slide presentation, which includes supplemental information related to LifeStance Health Group, is furnished as Exhibit 99.2. The information furnished under Item 7.01 of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 8.01 Other Items. On February 24, 2026, the Board of Directors of the Company approved a share repurchase program, which authorizes the Company to repurchase up to $100 million of the Company’s outstanding shares of common stock (the “Repurchase Program”). The Repurchase Program does not obligate the Company to repurchase any particular amount of common stock. Stock repurchases under this program may be made at such times, prices, amounts and on such terms as the Company may determine from time to time to be advisable based on a variety of factors such as the market price of th
See how LFST stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "LFST LifeStance Health Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.